These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
Edwards Lifesciences Corporation (NYSE:EW) reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.
爱德华生命科学公司（NYSE：EW）公布的第二季度销售业绩低于预期，并发布的第三季度指引低于预期。此外，该公司收购了JenaValve和Endotronix。
Edwards Lifesciences reported quarterly earnings of 70 cents per share which beat the analyst consensus estimate of 69 cents per share. The company reported quarterly sales of $1.632 billion which missed the analyst consensus estimate of $1.653 billion.
爱德华生命科学报告每股收益为0.7美元，超过分析师的预期，为0.69美元每股。该公司第二季度销售额为16.32亿美元，低于分析师的预期，为16.53亿美元。
"Second quarter total company sales growth of 8 percent reflected strong contributions from our rapidly growing TMTT product group, offset by lower-than-expected growth in TAVR," said Bernard Zovighian, CEO. "Edwards is well-positioned to deliver sustainable TAVR growth in 2025 and beyond, driven by advancements in our leading SAPIEN platform, indication expansions to much larger populations of patients, and improving patient access to this important therapy. Our vision for TMTT is becoming a reality, and our strategic commitment has developed into a growth portfolio of differentiated technologies. We are confident in Edwards' strategy in structural heart supported by the broadening TAVR opportunity, accelerating contributions of our TMTT therapies, and our expanding portfolio of structural heart innovations that addresses the unmet needs of millions of patients around the world."
“第二季度公司总销售额增长8％，反映出TMTt产品组的快速增长的强大贡献，抵消了TAVR增长低于预期的影响，”首席执行官Bernard Zovighian说。“Edwards在2025年及以后能够提供可持续的TAVR增长，是由我们领先的SAPIEN平台的发展推动，包括更大患者群体的适应扩张，以及改善患者接触这种重要治疗的方式。 TMTt的愿景正在成为现实，我们的战略承诺已经演变成卓越技术的增长组合。我们对Edwards发展结构性心脏的策略充满信心，该策略受到TAVR机遇的广泛支持，以及TMTt治疗的加速贡献和我们不断扩大的结构性心脏创新组合，以解决全球数百万患者未满足的需求。”
Edwards Lifesciences shares fell 28.4% to trade at $62.29 on Thursday.
爱德华生命科学股票周四下跌28.4%，交易价格为62.29美元。
These analysts made changes to their price targets on Edwards Lifesciences following the announcement.
这些分析师在爱德华生命科学公告后对其价格目标做出了更改。
- Baird analyst David Rescott downgraded Edwards Lifesciences from Outperform to Neutral and slashed the price target from $102 to $70.
- JP Morgan analyst Robbie Marcus downgraded the stock from Overweight to Neutral and cut the price target from $105 to $72.
- B of A Securities analyst Travis Steed downgraded Edwards Lifesciences from Buy to Neutral, while cutting the price target from $105 to $75.
- Piper Sandler analyst Adam Maeder maintained the stock with a Neutral and lowered the price target from $88 to $73.
- Canaccord Genuity analyst William Plovanic maintained Edwards Lifesciences with a Hold and slashed the price target from $85 to $77.
- Oppenheimer analyst Suraj Kalia maintained the stock with an Outperform rating and lowered the price target from $100 to $90.
- Stifel analyst Rick Wise maintained the stock with a Hold and slashed the price target from $85 to $70.
- RBC Capital analyst Shagun Singh maintained Edwards Lifesciences with an Outperform rating, while cutting the price target from $101 to $85.
- Deutsche Bank analyst Pito Chickering maintained the stock with a Buy and lowered the price target from $103 to $85.
- Evercore ISI Group analyst Vijay Kumar maintained Edwards Lifesciences with an In-Line rating and cut the price target from $91 to $76.
- 贝尔德的分析师大卫·雷斯科特（David Rescott）将爱德华生命科学的评级从跑赢大盘调降到中性，并将价格目标从102美元下调至70美元。
- JP摩根的分析师罗比·马库斯（Robbie Marcus）将该股票的评级从超配调降至中性，并将价格目标从105美元下调至72美元。
- 美国银行证券的分析师特拉维斯·斯蒂德（Travis Steed）将爱德华生命科学的评级从买入调降到中性，同时将价格目标从105美元下调至75美元。
- 派杰投资的分析师亚当·迈德（Adam Maeder）保持中立并将价格目标下调至73美元。
- Canaccord Genuity的分析师威廉·普洛万尼克（William Plovanic）维持爱德华生命科学的评级为持有，将价格目标从85美元下调至77美元。
- Oppenheimer的分析师Suraj Kalia保持跑赢大盘的评级并将价格目标下调至90美元。
- 斯蒂费尔的分析师Rick Wise维持持有评级，并将价格目标从85美元下调至70美元。
- RBC Capital的分析师Shagun Singh保持跑赢大盘评级，同时将价格目标从101美元下调至85美元。
- 德意志银行的分析师Pito Chickering维持购买评级，将价格目标从103美元下调至85美元。
- Evercore的分析师Vijay Kumar保持持有评级，并将价格目标从91美元下调至76美元。
- This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
- 这位Lululemon分析师不再看好；这是周四前五次下调。